{"id":369143,"date":"2025-12-08T15:00:37","date_gmt":"2025-12-08T09:30:37","guid":{"rendered":"https:\/\/www.scconline.com\/blog\/?p=369143"},"modified":"2025-12-08T14:50:13","modified_gmt":"2025-12-08T09:20:13","slug":"cam-advises-swiss-parenterals-30-percent-stake-acquisition-eris-lifesciences-2025","status":"publish","type":"post","link":"https:\/\/www.scconline.com\/blog\/post\/2025\/12\/08\/cam-advises-swiss-parenterals-30-percent-stake-acquisition-eris-lifesciences-2025\/","title":{"rendered":"Cyril Amarchand Mangaldas advises Swiss Parenterals Limited in acquisition of its 30% stake by Eris Lifesciences Limited"},"content":{"rendered":"<div style=\"text-align: justify; line-height: 150%;\">\n<p style=\"margin-bottom: 3%;\">Cyril Amarchand Mangaldas advises Swiss Parenterals Limited (&#8220;SPL&#8221;) and Mr. Naishadh Shah (&#8220;Seller&#8221;) in the proposed sale of the balance 30% stake of SPL to Eris Lifesciences Limited (&#8220;ELL&#8221;) for an aggregate consideration of INR 423,30,00,000 (Indian Rupees Four Hundred Twenty Three Crores and Thirty Lakhs). ELL will acquire such 30% stake from Seller for consideration other than cash, i.e. by way of issuance and allotment of 23,06,372 equity shares (constituting 1.69% of the share capital) of ELL to Seller, by way of a preferential issue under the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018.<\/p>\n<p style=\"margin-bottom: 3%;\">ELL, an Indian branded formulations company, for the expansion of its sterile injectables footprint had acquired majority equity stake in SPL, a leading player in the sterile injectables business in 80+ emerging markets across Africa, the Asia Pacific, and Latin America, in the year 2024. Upon closing of the proposed sale, which is subject to regulatory approvals, SPL will become a wholly owned subsidiary of ELL.<\/p>\n<p style=\"margin-bottom: 3%;\">Cyril Amarchand Mangaldas&#8217; team reviewed and negotiated the share purchase subscription agreement and various documents in relation to preferential allotment for SPL and the Seller and assisted with the execution and will be assisting with closing related aspects of the transaction.<\/p>\n<p style=\"margin-bottom: 3%;\">The General Corporate team of Cyril Amarchand Mangaldas advised on the transaction. The transaction team was led by Ravi Shah, Partner; with support from Arushi Bindal, Senior Associate; and Aesha Shah, Associate.<\/p>\n<p style=\"margin-bottom: 3%;\">The transaction was signed on 24th November, 2025.<\/p>\n<hr\/>\n<p>About Cyril Amarchand Mangaldas<\/p>\n<p style=\"margin-bottom: 3%;\">Cyril Amarchand Mangaldas (CAM) is India&#8217;s leading law firm with a global reputation of being trusted advisers to its clients. The Firm advises a large and diverse set of clients, including domestic and foreign commercial enterprises, financial institutions, private equity and venture capital funds, start-ups, government and regulatory bodies. The Firm&#8217;s generalists, specialists and senior ex-regulators expertly guide clients across a spectrum of transactions, sectors and regulations. With over 1100 lawyers including 220 Partners, the Firm is a full-service law firm with offices in key business centres at Mumbai, Delhi-NCR, Bengaluru, Ahmedabad, Hyderabad, Chennai, GIFT City, Singapore and Abu Dhabi.<\/p>\n<p style=\"margin-bottom: 3%;\">The Firm has been named &#8220;Law Firm of the Year 2025&#8221; and consistently recognised as &#8220;Best Overall Law Firm&#8221; by the IBLJ Indian Law Firm Awards. It received &#8220;National Law Firm of the Year: India&#8221; at the IFLR Asia-Pacific Awards for the second consecutive year in 2023 and 2022 and &#8220;Innovation in Advancing Markets&#8221; award at the FT Innovative Lawyers Asia Pacific 2022 Awards. The Firm also won &#8220;India Deal Firm of the Year&#8221; at the ALB India Awards and &#8220;Firm of the Year&#8221; at the IFLR1000 India Awards in 2022.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p style=\"font-style: italic;\">Cyril Amarchand Mangaldas advised Swiss Parenterals Limited and its promoter on the sale of the remaining 30% stake to Eris Lifesciences Limited through a preferential allotment deal worth &#8377;423.30 crore.<\/p>\n","protected":false},"author":67011,"featured_media":369146,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[45282,2],"tags":[94376,94381,94380,94374,94375,94377,94378,94379],"class_list":["post-369143","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-law-firms-news","category-news","tag-30-stake-acquisition-india","tag-ahmedabad-corporate-legal-news","tag-cam-deal-team-advisory","tag-cyril-amarchand-mangaldas-deal-advisory","tag-eris-lifesciences-swiss-parenterals-acquisition","tag-pharmaceutical-ma-india-2025","tag-preferential-allotment-transaction","tag-sebi-icdr-regulations-deal"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.4 (Yoast SEO v26.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>CAM Advises Swiss Parenterals on Eris Lifesciences 30% Stake Acquisition | SCC Times<\/title>\n<meta name=\"description\" content=\"CAM advised Swiss Parenterals on selling its remaining 30% stake to Eris Lifesciences via a \u20b9423.30 crore preferential allotment transaction.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.scconline.com\/blog\/post\/2025\/12\/08\/cam-advises-swiss-parenterals-30-percent-stake-acquisition-eris-lifesciences-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cyril Amarchand Mangaldas advises Swiss Parenterals Limited in acquisition of its 30% stake by Eris Lifesciences Limited\" \/>\n<meta property=\"og:description\" content=\"CAM advised Swiss Parenterals on selling its remaining 30% stake to Eris Lifesciences via a \u20b9423.30 crore preferential allotment transaction.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.scconline.com\/blog\/post\/2025\/12\/08\/cam-advises-swiss-parenterals-30-percent-stake-acquisition-eris-lifesciences-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"SCC Times\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/scc.online\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-08T09:30:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2025\/12\/CAM-Swiss-Parenterals-Eris-Lifesciences-acquisition.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"886\" \/>\n\t<meta property=\"og:image:height\" content=\"590\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Editor\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Cyril Amarchand Mangaldas advises Swiss Parenterals Limited in acquisition of its 30% stake by Eris Lifesciences Limited\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Editor\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.scconline.com\/blog\/post\/2025\/12\/08\/cam-advises-swiss-parenterals-30-percent-stake-acquisition-eris-lifesciences-2025\/\",\"url\":\"https:\/\/www.scconline.com\/blog\/post\/2025\/12\/08\/cam-advises-swiss-parenterals-30-percent-stake-acquisition-eris-lifesciences-2025\/\",\"name\":\"CAM Advises Swiss Parenterals on Eris Lifesciences 30% Stake Acquisition | SCC Times\",\"isPartOf\":{\"@id\":\"https:\/\/www.scconline.com\/blog\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.scconline.com\/blog\/post\/2025\/12\/08\/cam-advises-swiss-parenterals-30-percent-stake-acquisition-eris-lifesciences-2025\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.scconline.com\/blog\/post\/2025\/12\/08\/cam-advises-swiss-parenterals-30-percent-stake-acquisition-eris-lifesciences-2025\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2025\/12\/CAM-Swiss-Parenterals-Eris-Lifesciences-acquisition.webp\",\"datePublished\":\"2025-12-08T09:30:37+00:00\",\"author\":{\"@id\":\"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/84e42bab48238baf12c7e33b3d9761fe\"},\"description\":\"CAM advised Swiss Parenterals on selling its remaining 30% stake to Eris Lifesciences via a \u20b9423.30 crore preferential allotment transaction.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.scconline.com\/blog\/post\/2025\/12\/08\/cam-advises-swiss-parenterals-30-percent-stake-acquisition-eris-lifesciences-2025\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.scconline.com\/blog\/post\/2025\/12\/08\/cam-advises-swiss-parenterals-30-percent-stake-acquisition-eris-lifesciences-2025\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.scconline.com\/blog\/post\/2025\/12\/08\/cam-advises-swiss-parenterals-30-percent-stake-acquisition-eris-lifesciences-2025\/#primaryimage\",\"url\":\"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2025\/12\/CAM-Swiss-Parenterals-Eris-Lifesciences-acquisition.webp\",\"contentUrl\":\"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2025\/12\/CAM-Swiss-Parenterals-Eris-Lifesciences-acquisition.webp\",\"width\":886,\"height\":590,\"caption\":\"CAM Swiss Parenterals Eris Lifesciences acquisition\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.scconline.com\/blog\/post\/2025\/12\/08\/cam-advises-swiss-parenterals-30-percent-stake-acquisition-eris-lifesciences-2025\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.scconline.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cyril Amarchand Mangaldas advises Swiss Parenterals Limited in acquisition of its 30% stake by Eris Lifesciences Limited\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.scconline.com\/blog\/#website\",\"url\":\"https:\/\/www.scconline.com\/blog\/\",\"name\":\"SCC Times\",\"description\":\"Bringing you the Best Analytical Legal News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.scconline.com\/blog\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/84e42bab48238baf12c7e33b3d9761fe\",\"name\":\"Editor\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/34e366be721c41333586de05faa13743195f5b142dcd7a015c6fabd2389521d0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/34e366be721c41333586de05faa13743195f5b142dcd7a015c6fabd2389521d0?s=96&d=mm&r=g\",\"caption\":\"Editor\"},\"url\":\"https:\/\/www.scconline.com\/blog\/post\/author\/editor_4\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CAM Advises Swiss Parenterals on Eris Lifesciences 30% Stake Acquisition | SCC Times","description":"CAM advised Swiss Parenterals on selling its remaining 30% stake to Eris Lifesciences via a \u20b9423.30 crore preferential allotment transaction.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.scconline.com\/blog\/post\/2025\/12\/08\/cam-advises-swiss-parenterals-30-percent-stake-acquisition-eris-lifesciences-2025\/","og_locale":"en_US","og_type":"article","og_title":"Cyril Amarchand Mangaldas advises Swiss Parenterals Limited in acquisition of its 30% stake by Eris Lifesciences Limited","og_description":"CAM advised Swiss Parenterals on selling its remaining 30% stake to Eris Lifesciences via a \u20b9423.30 crore preferential allotment transaction.","og_url":"https:\/\/www.scconline.com\/blog\/post\/2025\/12\/08\/cam-advises-swiss-parenterals-30-percent-stake-acquisition-eris-lifesciences-2025\/","og_site_name":"SCC Times","article_publisher":"https:\/\/www.facebook.com\/scc.online\/","article_published_time":"2025-12-08T09:30:37+00:00","og_image":[{"width":886,"height":590,"url":"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2025\/12\/CAM-Swiss-Parenterals-Eris-Lifesciences-acquisition.jpg","type":"image\/jpeg"}],"author":"Editor","twitter_card":"summary_large_image","twitter_title":"Cyril Amarchand Mangaldas advises Swiss Parenterals Limited in acquisition of its 30% stake by Eris Lifesciences Limited","twitter_misc":{"Written by":"Editor","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.scconline.com\/blog\/post\/2025\/12\/08\/cam-advises-swiss-parenterals-30-percent-stake-acquisition-eris-lifesciences-2025\/","url":"https:\/\/www.scconline.com\/blog\/post\/2025\/12\/08\/cam-advises-swiss-parenterals-30-percent-stake-acquisition-eris-lifesciences-2025\/","name":"CAM Advises Swiss Parenterals on Eris Lifesciences 30% Stake Acquisition | SCC Times","isPartOf":{"@id":"https:\/\/www.scconline.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.scconline.com\/blog\/post\/2025\/12\/08\/cam-advises-swiss-parenterals-30-percent-stake-acquisition-eris-lifesciences-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.scconline.com\/blog\/post\/2025\/12\/08\/cam-advises-swiss-parenterals-30-percent-stake-acquisition-eris-lifesciences-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2025\/12\/CAM-Swiss-Parenterals-Eris-Lifesciences-acquisition.webp","datePublished":"2025-12-08T09:30:37+00:00","author":{"@id":"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/84e42bab48238baf12c7e33b3d9761fe"},"description":"CAM advised Swiss Parenterals on selling its remaining 30% stake to Eris Lifesciences via a \u20b9423.30 crore preferential allotment transaction.","breadcrumb":{"@id":"https:\/\/www.scconline.com\/blog\/post\/2025\/12\/08\/cam-advises-swiss-parenterals-30-percent-stake-acquisition-eris-lifesciences-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.scconline.com\/blog\/post\/2025\/12\/08\/cam-advises-swiss-parenterals-30-percent-stake-acquisition-eris-lifesciences-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.scconline.com\/blog\/post\/2025\/12\/08\/cam-advises-swiss-parenterals-30-percent-stake-acquisition-eris-lifesciences-2025\/#primaryimage","url":"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2025\/12\/CAM-Swiss-Parenterals-Eris-Lifesciences-acquisition.webp","contentUrl":"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2025\/12\/CAM-Swiss-Parenterals-Eris-Lifesciences-acquisition.webp","width":886,"height":590,"caption":"CAM Swiss Parenterals Eris Lifesciences acquisition"},{"@type":"BreadcrumbList","@id":"https:\/\/www.scconline.com\/blog\/post\/2025\/12\/08\/cam-advises-swiss-parenterals-30-percent-stake-acquisition-eris-lifesciences-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.scconline.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Cyril Amarchand Mangaldas advises Swiss Parenterals Limited in acquisition of its 30% stake by Eris Lifesciences Limited"}]},{"@type":"WebSite","@id":"https:\/\/www.scconline.com\/blog\/#website","url":"https:\/\/www.scconline.com\/blog\/","name":"SCC Times","description":"Bringing you the Best Analytical Legal News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.scconline.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/84e42bab48238baf12c7e33b3d9761fe","name":"Editor","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/34e366be721c41333586de05faa13743195f5b142dcd7a015c6fabd2389521d0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/34e366be721c41333586de05faa13743195f5b142dcd7a015c6fabd2389521d0?s=96&d=mm&r=g","caption":"Editor"},"url":"https:\/\/www.scconline.com\/blog\/post\/author\/editor_4\/"}]}},"jetpack_featured_media_url":"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2025\/12\/CAM-Swiss-Parenterals-Eris-Lifesciences-acquisition.webp","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":368864,"url":"https:\/\/www.scconline.com\/blog\/post\/2025\/12\/05\/sam-advises-eris-lifesciences-acquisition-swiss-parenterals\/","url_meta":{"origin":369143,"position":0},"title":"Shardul Amarchand Mangaldas Advises Eris Lifesciences Limited on the Acquisition of Remaining Stake in Swiss Parenterals Limited","author":"Editor","date":"December 5, 2025","format":false,"excerpt":"SAM advised Eris Lifesciences on acquiring the remaining 30% stake in Swiss Parenterals, making it a wholly owned subsidiary.","rel":"","context":"In &quot;Law Firms News&quot;","block_context":{"text":"Law Firms News","link":"https:\/\/www.scconline.com\/blog\/post\/category\/news\/law-firms-news\/"},"img":{"alt_text":"Eris Lifesciences Swiss Parenterals acquisition","src":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2025\/12\/Eris-Lifesciences-Swiss-Parenterals-acquisition.webp?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2025\/12\/Eris-Lifesciences-Swiss-Parenterals-acquisition.webp?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2025\/12\/Eris-Lifesciences-Swiss-Parenterals-acquisition.webp?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2025\/12\/Eris-Lifesciences-Swiss-Parenterals-acquisition.webp?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":315201,"url":"https:\/\/www.scconline.com\/blog\/post\/2024\/02\/24\/shardul-amarchand-mangaldas-co-advises-eris-lifesciences-limited-on-the-acquisition-of-a-majority-stake-in-swiss-parenterals-limited\/","url_meta":{"origin":369143,"position":1},"title":"Shardul Amarchand Mangaldas &amp; Co. advises Eris Lifesciences Limited on the acquisition of a majority stake in Swiss Parenterals Limited","author":"Bhumika Indulia","date":"February 24, 2024","format":false,"excerpt":"Shardul Amarchand Mangaldas advised Eris Lifesciences Limited (\u201cEris\u201d) on the acquisition of a majority stake in Swiss Parenterals Limited (\u201cSPL\u201d) from the existing shareholders of SPL by Eris and certain individual purchasers. The aggregate deal value is approximately INR 875 Crores (USD 105.38 million). The consideration was paid through a\u2026","rel":"","context":"In &quot;Law Firms News&quot;","block_context":{"text":"Law Firms News","link":"https:\/\/www.scconline.com\/blog\/post\/category\/news\/law-firms-news\/"},"img":{"alt_text":"Eris Lifesciences Limited","src":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/02\/Eris-Lifesciences-Limited.webp?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/02\/Eris-Lifesciences-Limited.webp?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/02\/Eris-Lifesciences-Limited.webp?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/02\/Eris-Lifesciences-Limited.webp?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":308625,"url":"https:\/\/www.scconline.com\/blog\/post\/2023\/12\/07\/sam-advises-eris-lifesciences-limited-acquisition-of-dermatology-and-nephrology-branded-formulations-business-units\/","url_meta":{"origin":369143,"position":2},"title":"SAM advises Eris Lifesciences Limited on its acquisition of Dermatology and Nephrology branded formulations business units of Biocon Biologics Limited in India","author":"Bhumika Indulia","date":"December 7, 2023","format":false,"excerpt":"Shardul Amarchand Mangaldas advised Eris Lifesciences Limited (\u201cEris\u201d) on its acquisition of Dermatology and Nephrology branded formulations business units of Biocon Biologics Limited (\u201cBiocon\u201d) in India. The deal is valued at approximately INR 366 crores and the date of closing the deal was 10 November 2023. This acquisition marks the\u2026","rel":"","context":"In &quot;Law Firms News&quot;","block_context":{"text":"Law Firms News","link":"https:\/\/www.scconline.com\/blog\/post\/category\/news\/law-firms-news\/"},"img":{"alt_text":"Eris Lifesciences Limited","src":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/12\/Texmaco-Rail-Engineering-Limited.webp?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/12\/Texmaco-Rail-Engineering-Limited.webp?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/12\/Texmaco-Rail-Engineering-Limited.webp?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/12\/Texmaco-Rail-Engineering-Limited.webp?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":283450,"url":"https:\/\/www.scconline.com\/blog\/post\/2023\/02\/08\/khaitan-co-advises-eris-group-on-its-acquisition-of-a-part-of-the-dermatology-portfolio-of-glenmark-pharmaceuticals-limited\/","url_meta":{"origin":369143,"position":3},"title":"Khaitan &amp; Co. advises Eris Group on its acquisition of a part of the dermatology portfolio of Glenmark Pharmaceuticals Limited","author":"Bhumika Indulia","date":"February 8, 2023","format":false,"excerpt":"DEAL DETAILS Eris Lifesciences Limited | Brand agreement and supply of agreement between Eris Lifesciences Limited and Glenmark Pharmaceuticals Limited NO HEADINGS DETAILS 1. Sector Pharmaceutical Industry 2. Announcement Date 17-Jan-2023 3. Completion Date 17-Jan-2023 4. Name of Client Eris Lifesciences Limited Eris Lifesciences Ltd is a publicly listed Indian\u2026","rel":"","context":"In &quot;Law Firms News&quot;","block_context":{"text":"Law Firms News","link":"https:\/\/www.scconline.com\/blog\/post\/category\/news\/law-firms-news\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/02\/MicrosoftTeams-image-339.jpg?resize=350%2C200&ssl=1","width":350,"height":200},"classes":[]},{"id":287398,"url":"https:\/\/www.scconline.com\/blog\/post\/2023\/03\/21\/khaitan-co-advises-eris-lifesciences-limited-on-its-acquisition-of-a-part-of-the-dermatology-portfolio-of-dr-reddys-laboratories-limited\/","url_meta":{"origin":369143,"position":4},"title":"Khaitan &amp; Co advises Eris Lifesciences Limited on its acquisition of a part of the dermatology portfolio of Dr. Reddy&#8217;s Laboratories Limited","author":"Bhumika Indulia","date":"March 21, 2023","format":false,"excerpt":"Khaitan & Co has advised Eris Lifesciences Limited on its acquisition of a part of the dermatology portfolio of Dr. Reddy's Laboratories Limited for a total consideration of INR 275 crores. The acquisition helps augment and expand the dermatology business of Eris Lifesciences in India. The team assisted in drafting,\u2026","rel":"","context":"In &quot;Law Firms News&quot;","block_context":{"text":"Law Firms News","link":"https:\/\/www.scconline.com\/blog\/post\/category\/news\/law-firms-news\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/03\/MicrosoftTeams-image-811.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/03\/MicrosoftTeams-image-811.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/03\/MicrosoftTeams-image-811.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2023\/03\/MicrosoftTeams-image-811.png?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":317745,"url":"https:\/\/www.scconline.com\/blog\/post\/2024\/03\/19\/khaitan-co-advises-eris-lifesciences-limited-on-its-acquisition-of-the-branded-formulations-business-of-biocon-biologics-limited-in-india\/","url_meta":{"origin":369143,"position":5},"title":"Khaitan &amp; Co advises Eris Lifesciences Limited on its acquisition of the branded formulations business of Biocon Biologics Limited in India","author":"Bhumika Indulia","date":"March 19, 2024","format":false,"excerpt":"DEAL DETAILS Eris Lifesciences Limited | Acquisition of the Indian branded formulations business of Biocon Biologics Limited Khaitan & Co advised Eris Lifesciences Limited on its acquisition of the branded formulations business of Biocon Biologics Limited in India for a total consideration of INR 1,242 Crores. The acquisition helps augment\u2026","rel":"","context":"In &quot;Law Firms News&quot;","block_context":{"text":"Law Firms News","link":"https:\/\/www.scconline.com\/blog\/post\/category\/news\/law-firms-news\/"},"img":{"alt_text":"Eris Lifesciences Limited","src":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/03\/biocon.webp?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/03\/biocon.webp?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/03\/biocon.webp?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2024\/03\/biocon.webp?resize=700%2C400&ssl=1 2x"},"classes":[]}],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/posts\/369143","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/users\/67011"}],"replies":[{"embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/comments?post=369143"}],"version-history":[{"count":0,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/posts\/369143\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/media\/369146"}],"wp:attachment":[{"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/media?parent=369143"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/categories?post=369143"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/tags?post=369143"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}